Mukul Agrawal's Pharma Multibagger Stock from Its 52-Week Low; Successfully Completes Inspection
Stock has emerged as a multibagger, rallying an impressive 100 per cent from its 52-week low recorded in June 2024
CARBOGEN AMCIS AG, a wholly-owned subsidiary of Dishman Carbogen Amcis Limited, has successfully completed the Swissmedic inspection of its Vionnaz facility in Switzerland. This milestone reaffirms the site’s adherence to high regulatory standards and its commitment to delivering quality in pharmaceutical development and manufacturing.
The Swiss Agency for Therapeutic Products (Swissmedic) conducted a routine two-day inspection in November 2024. The inspection, led by the Regional Medicines Inspectorate of Western Switzerland, focused on evaluating the Quality Management System for the development and manufacture of highly potent Active Pharmaceutical Ingredients (APIs), including analytical and quality control processes. Following the inspection, the facility’s Good Manufacturing Practice (GMP) certification was renewed.
Hélène Mazuel, Quality Director at CARBOGEN AMCIS, expressed pride in the Vionnaz team, stating:
“This successful inspection underscores our track record of delivering high-quality development and manufacturing services. Demonstrating our ability to meet all aspects of quality to Swissmedic is a significant milestone that further strengthens our reputation.”
The share price of Dishman Carbogen Amcis Ltd has emerged as a multibagger, rallying an impressive 100 per cent from its 52-week low recorded in June 2024. Notably, ace investor Mukul Mahavir Agrawal holds a substantial 5.50 per cent stake in the company, amounting to 86,17,000 shares.
About the Vionnaz Facility
Acquired in 2014, the Vionnaz site specializes in the development and small-scale production of highly potent APIs, including components for antibody-drug conjugates (ADCs). The facility boasts three process development laboratories, a dedicated quality control laboratory, production units with reactors up to 30 liters, preparative chromatography systems, and freeze dryers for pilot-scale production.
This achievement marks another chapter in the facility’s compliance history, following successful inspections since its first in 2015. It highlights CARBOGEN AMCIS’s consistent commitment to meeting Swissmedic’s stringent standards.
About CARBOGEN AMCIS
CARBOGEN AMCIS, headquartered in Switzerland, provides comprehensive drug development and commercialization services to the pharmaceutical and biopharmaceutical sectors. As part of the Dishman Carbogen Amcis group, the company supports its clients across all stages of clinical development and product life cycles, offering innovative chemistry solutions and integrated services.
About Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited is a global outsourcing partner for the pharmaceutical industry, offering development, scale-up, and manufacturing solutions across its facilities in Europe, China, and India. The group’s focus on quality and compliance continues to drive its reputation as a trusted partner in the pharmaceutical value chain.
Disclaimer: The article is for informational purposes only and not investment advice.